GGI
VVOS icon

Godsey & Gibb Inc’s Vivos Therapeutics VVOS Stock Holding History

Godsey & Gibb Inc’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,720
Closed -$47.4K – 376
2023
Q2 		$47.4K Hold
3,720
– – 0.01% 171
2023
Q1 		$31.7K Buy
+3,720
New +$81.4K ﹤0.01% 185

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AF
Apexium Financial Dallas, Texas $2.06B AUM 15.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Godsey & Gibb Inc's VVOS Position: Q3 2023 in Review

Godsey & Gibb Inc sold out of Vivos Therapeutics (VVOS) in Q3 2023, closing a stake of 3,720 shares — an estimated $47.4K sold.

Godsey & Gibb Inc first reported a position in VVOS in Q1 2023 and held it in 2 quarters. The position peaked at $47.4K in Q2 2023. 28 funds tracked by Wall St. Rank hold VVOS as of Q3 2023.

  • Godsey & Gibb Inc reported no remaining Vivos Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Godsey & Gibb Inc sold 3,720 Vivos Therapeutics shares in Q3 2023, an estimated $47.4K.
  • Godsey & Gibb Inc first reported a position in Vivos Therapeutics in Q1 2023 and held it in 2 quarters.
  • Godsey & Gibb Inc's Vivos Therapeutics position peaked at $47.4K in Q2 2023.
  • 28 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2023.

Based on Godsey & Gibb Inc's 13F filing for Q3 2023, filed 25 Oct 2023.